Kawasaki Disease and Dental Approaches

Yıl 2020, , 989 - 1001, 30.11.2020

Merve Candan , İrem İpek , Murat Ünal

https://doi.org/10.33715/inonusaglik.753219

Öz

Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is a self-limiting medium-sized muscular artery vasculitis and is the most common cause of acquired heart disease in children in developed countries. The disease mostly affects children under 5 years old. In the treatment of KD, use of intravenous immunoglobulin (IVIG) together with acetylsalicylic acid (ASA) is accepted as the standard treatment. Early diagnosis and treatment is very important in this childhood disease, which has life-long complications such as thrombosis, coronary stenosis, myocardial infarction, calcifications, the rupture of giant coronary artery aneurysm and sudden death. The frequent occurrence of oral symptoms in KD indicates that pediatric dentists may play a role in the diagnosis of KD. Also, the symptoms, treatment and complications of KD affect the approach of dentists to patients during dental treatment procedures. The aim of this review is to share current information about KD which has come to the agenda during the COVID-19 pandemic that affected the world, and to guide the dentist's approaches during dental treatment of these patients.

Anahtar Kelimeler

CHILDHOOD DISEASES, DENTAL APPROACHES, KAWASAKI DISEASE

KAWASAKİ HASTALIĞI VE DENTAL YAKLAŞIMLAR

Öz

Mukokutanöz lenf nodu sendromu olarak da bilinen Kawasaki hastalığı (KH), kendini sınırlayan orta çaplı musküler arter vasküliti olup, gelişmiş ülkelerdeki çocuklarda edinilmiş kalp hastalığının en yaygın nedenidir. Hastalık çoğunlukla 5 yaşın altındaki çocukları etkiler. KH’ nin tedavisinde intravenöz immünoglobulin (IVIG) ile birlikte asetil salisilik asit (ASA) kullanımı standart tedavi olarak kabul edilir. Yaşam boyu tromboz, koroner stenoz, miyokard enfarktüsü, kalsifikasyonlar, dev koroner arter anevrizması rüptürü ve ani ölüm gibi komplikasyonları olan bu çocukluk çağı hastalığının, erken tanı ve tedavisi çok önemlidir. KH’ de oral bulguların sıkça görülmesi, özellikle pediatrik diş hekimlerinin KH tanısında rol alabileceğini gösterir. Ayrıca KH bulguları, tedavisi ve komplikasyonları dental tedavi prosedürleri sırasında diş hekimlerinin hastalara yaklaşımlarını etkiler. Bu derlemenin amacı, tüm dünyayı etkileyen COVID-19 pandemisi döneminde yeniden gündeme gelen KH hakkındaki güncel bilgileri paylaşmak ve bu hastaların dental tedavileri sırasında diş hekimlerinin yaklaşımlarına yol gösterici olmaktır.

Anahtar Kelimeler

ÇOCUKLUK HASTALIKLARI, DENTAL YAKLAŞIMLAR, KAWASAKİ HASTALIĞI

Kaynakça

• Asano, T., Ogawa, S. (2000). Expression of monocyte chemoattractant protein-1 in Kawasaki disease: The anti-inflammatory effect of gamma globulin therapy. Scandinavian Journal of Immunology, 51(1), 98-103.
• Cahill, T. J., Harrison, J. L., Jewell, P., Onakpoya, I., Chambers, J. B., Dayer, M., … Prendergast, B. D. (2017). Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-analysis. Heart (British Cardiac Society), 103(12), 937-944.
• Chambers, S. T., Murdoch, D., Morris, A., Holland, D., Pappas, P., Almela, M., …International Collaboration on Endocarditis Prospective Cohort Study Investigators. (2013). HACEK infective endocarditis: Characteristics and outcomes from a large, multi-national cohort. PloS One, 8(5), e63181.
• Chapman, J., Arnold, J. K. (2020). Reye Syndrome. Içinde StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK526101/
• Denby, K. J., Clark, D. E., Markham, L. W. (2017). Management of Kawasaki disease in adults. Heart (British Cardiac Society), 103(22), 1760-1769.
• Furukawa, S., Matsubara, T., Umezawa, Y., Okumura, K., Yabuta, K. (1994). Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. The Journal of Pediatrics, 124(5 Pt 1), 721-725.
• Holman, R. C., Christensen, K. Y., Belay, E. D., Steiner, C. A., Effler, P. V., Miyamura, J., … Melish, M. (2010). Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Medical Journal, 69(8), 194-197.
• Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Bradley Segal, J., … Mathew, R. (2020). COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hospital Pediatrics,10(6), 537-540.
• Kumrah, R., Vignesh, P., Rawat, A., Singh, S. (2020). Immunogenetics of Kawasaki disease. Clinical Reviews in Allergy & Immunology, 59, 122–139.
• Magrum, B. G., Pickworth, K. K. (2020). Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 77(2), 123-127.
• Makino, N., Nakamura, Y., Yashiro, M., Ae, R., Tsuboi, S., Aoyama, Y., … Yanagawa, H. (2015). Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: From the results of the 22nd nationwide survey. Journal of Epidemiology, 25(3), 239-245.
• McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M., … American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 135(17), e927-e999.
• Modesti, A. M., Plewa, M. C. (2020). Kawasaki Disease. Içinde StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK537163/
• Nakamura, Y. (2018). Kawasaki disease: Epidemiology and the lessons from it. International Journal of Rheumatic Diseases, 21(1), 16-19.
• Napeñas, J. J., Oost, F. C. D., DeGroot, A., Loven, B., Hong, C. H. L., Brennan, M. T., … van Diermen, D. E. (2013). Review of postoperative bleeding risk in dental patients on antiplatelet therapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 115(4), 491-499.
• Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y., Burns, J. C., … Taubert, K. A. (2004). Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics, 114(6), 1708-1733.
• Ohno, T., Yuge, T., Kariyazono, H., Igarashi, H., Joh-o, K., Kinugawa, N., … Hara, T. (2002). Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. European Journal of Pediatrics, 161(2), 105-111.
• Özen, S., Bakkaloglu, A., Dusunsel, R., Soylemezoglu, O., Ozaltin, F., Poyrazoglu, H., … Kural, N. (2007). Turkish Pediatric Vasculitis Study Group. Childhood vasculitides in Turkey: a nationwide survey. Clinical rheumatology, 26(2), 196–200.
• Red Book, 30th Edition (2015) | AAP eBooks (30th Edition). (t.y.). 24 Temmuz 2020 tarihinde https://ebooks.aappublications.org/content/red-book-30th-edition-2015 adresinden erişildi.
• Ringel, R., Maas, R. (2016). Dental procedures in patients treated with antiplatelet or oral anticoagulation therapy—An anonymous survey. Gerodontology, 33(4), 447-452.
• Rowley, A. H., Shulman, S. T., Spike, B. T., Mask, C. A., Baker, S. C. (2001). Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. Journal of Immunology (Baltimore, Md.: 1950), 166(2), 1334-1343.
• Rowley, A. H., Shulman, S. T. (2018). The epidemiology and pathogenesis of Kawasaki Disease. Frontiers in Pediatrics, 6.
• Saguil, A., Fargo, M. V., Grogan, S. P. (2015). Diagnosis and management of Kawasaki Disease. American Family Physician, 91(6), 365-371.
• Sánchez-Manubens, J., Bou, R., Anton, J. (2014). Diagnosis and classification of Kawasaki disease. Journal of Autoimmunity, 48-49, 113-117.
• SDCEP-Anticoagulants-Quick-Reference-Guide.pdf. (t.y.). 20 Mayıs 2020 tarihinde http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Quick-Reference-Guide.pdf adresinden erişildi.
• Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., … Hoen, B. (2012). Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey. Clinical Infectious Diseases, 54(9), 1230-1239.
• Singh, S., Jindal, A. K., Pilania, R. K. (2018). Diagnosis of Kawasaki disease. International Journal of Rheumatic Diseases, 21(1), 36-44.
• Sosa, T., Brower, L., Divanovic, A. (2019). Diagnosis and Management of Kawasaki Disease. JAMA Pediatrics, 173(3), 278-279.
• Sudo, D., Nakamura, Y. (2017). Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatrica (Oslo, Norway: 1992), 106(5), 796-800.
• Tang, B., Lo, H. H., Lei, C., U, K. I., Wendy Hsiao, W-L., Guo, X., … Law, B. Y.-K. (2020). Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 70, 153208.
• Toyoda, N., Chikwe, J., Itagaki, S., Gelijns, A. C., Adams, D. H., Egorova, N. N. (2017). Trends in Infective Endocarditis in California and New York State, 1998-2013. JAMA, 317(16), 1652-1660.
• Wei, Y. J., Zhao, X. L., Liu, B. M., Niu, H., Li, Q. (2016). cardiac complications in 38 cases of Kawasaki Disease with coronary artery aneurysm diagnosed by Echocardiography. Echocardiography (Mount Kisco, N.Y.), 33(5), 764-770.
• Wilson, W., Taubert, K. A., Gewitz, M., Lockhart, P. B., Baddour, L. M., Levison, M., … Newburger, J. W. (2007). Quality of care and outcomes research ınterdisciplinary working group. Prevention of infective endocarditis: Guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation, 116(15), 1736-1754.
• Yeung, R. S. M. (2005). Pathogenesis and treatment of Kawasaki’s disease. Current Opinion in Rheumatology, 17(5), 617-623.
• Yumoto, H., Hirota, K., Hirao, K., Ninomiya, M., Murakami, K., Fujii, H.,… Miyake, Y. (2019). The pathogenic factors from oral streptococci for systemic diseases. International Journal of Molecular Sciences, 20(18).
• Zhang, B., Hao, Y., Zhang, Y., Yang, N., Li, H., Liang, J. (2019). Kawasaki disease manifesting as bilateral facial nerve palsy and meningitis: A case report and literature review. The Journal of International Medical Research, 47(8), 4014-4018.